As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.
The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback